2cureX Q2: Patiently waiting - Redeye

Redeye comments on 2cureX’s Q2’22 report. Operational activities are progressing well, laying the fundaments for a commercial roll-out However, Redeye notes a slow sales ramp up for 2cureX in Q2. We will return with a research update, where we will review our financial forecasts and fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/853531/2curex-q2-patiently-waiting?utm_source=finwire&utm_medium=RSS